Literature DB >> 12396776

Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report.

Michael Cox1, John Tripp, Sarah Blacksell.   

Abstract

OBJECTIVES: This study was undertaken to determine the performance of the levonorgestrel intrauterine system (LNG IUS) in British women in routine clinical use.
DESIGN: Doctors working in general practice and at family planning clinics throughout the UK who collaborate in the UK Family Planning and Reproductive Health Research Network were responsible for the fitting of 678 LNG IUSs.
RESULTS: Gross cumulative event rates at 5 years per 100 women were pregnancy 1.0, expulsion 5.9, removal for bleeding problems 16.7, removal for pain 4.3, and removal for pelvic inflammatory disease (PID) 1.2. Removals were also required for side effects that may be due to absorbed levonorgestrel. Positive effects include effective contraception and considerably reduced quantity of bleeding for most participants.
CONCLUSIONS: A need was identified to counsel women about the early bleeding problems including the possibility of oligomenorrhoea or amenorrhoea. This is considered to be very important as it will help women to persevere so that they can enjoy the longer-term benefits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396776     DOI: 10.1783/147118902101196225

Source DB:  PubMed          Journal:  J Fam Plann Reprod Health Care        ISSN: 1471-1893


  10 in total

Review 1.  Reproductive Planning and Contraception for Women with Inflammatory Bowel Diseases.

Authors:  Lori M Gawron; Jessica Sanders; Katelyn P Steele; Ann D Flynn
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325

2.  Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.

Authors:  Megan A Cohen; Katharine B Simmons; Alison B Edelman; Jeffrey T Jensen
Journal:  Contraception       Date:  2019-06-18       Impact factor: 3.375

3.  Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding.

Authors:  P Warner; A Guttinger; A F Glasier; R J Lee; S Nickerson; R M Brenner; H O D Critchley
Journal:  Hum Reprod       Date:  2009-11-07       Impact factor: 6.918

4.  Sex-Specific Issues in Inflammatory Bowel Disease.

Authors:  Elizabeth Rosenblatt; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-09

5.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Fertility and Contraception in Women With Inflammatory Bowel Disease.

Authors:  Jason Martin; Sunanda V Kane; Linda A Feagins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

Review 7.  Updates on Women's Health Issues in Patients with Inflammatory Bowel Disease.

Authors:  Nirupama Bonthala; Sunanda Kane
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

Review 8.  Optimizing the Care and Health of Women with Inflammatory Bowel Disease.

Authors:  Judy Nee; Joseph D Feuerstein
Journal:  Gastroenterol Res Pract       Date:  2015-05-21       Impact factor: 2.260

9.  Role of the levonorgestrel intrauterine system in effective contraception.

Authors:  Abdelhamid M Attia; Magdy M Ibrahim; Ahmed M Abou-Setta
Journal:  Patient Prefer Adherence       Date:  2013-08-09       Impact factor: 2.711

10.  Acute urticaria: an extremely rare adverse effect of levonorgestrel-releasing intrauterine system as a possible manifestation of progestogen hypersensitivity syndrome.

Authors:  Justyna Emeryk-Maksymiuk; Anna Grzywa-Celińska; Sławomir Woźniak; Piotr Szkodziak; Michał Szczyrek
Journal:  Postepy Dermatol Alergol       Date:  2018-07-19       Impact factor: 1.837

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.